ClariVest Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

ClariVest Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,360	Closed	-$256K	–	747
2023 Q1	$256K	Sell	14,360 -2,140	-13%	-$53.7K	0.01%	416
2022 Q4	$481K	Sell	16,500 -300	-2%	-$7.71K	0.02%	387
2022 Q3	$412K	Buy	+16,800	New	+$312K	0.02%	385
2020 Q2	–	Sell	-14,800	Closed	-$225K	–	839
2020 Q1	$225K	Buy	+14,800	New	+$265K	0.01%	477

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

ClariVest Asset Management's RYTM Position: Q2 2023 in Review

ClariVest Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2023, closing a stake of 14,360 shares — an estimated $256K sold.

ClariVest Asset Management first reported a position in RYTM in Q1 2020 and held it in 4 quarters. The position peaked at $481K in Q4 2022. 116 funds tracked by Wall St. Rank hold RYTM as of Q2 2023.

ClariVest Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
ClariVest Asset Management sold 14,360 Rhythm Pharmaceuticals shares in Q2 2023, an estimated $256K.
ClariVest Asset Management first reported a position in Rhythm Pharmaceuticals in Q1 2020 and held it in 4 quarters.
ClariVest Asset Management's Rhythm Pharmaceuticals position peaked at $481K in Q4 2022.
116 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2023.

Based on ClariVest Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.